Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a paper on X by Samir M. Hanash et al. published in Cell Reports Medicine:
“EGFR TKI–induced surfaceome remodeling in LUAD.
EGFR inhibition upregulates placental alkaline phosphatase via FoxO3a activation in EGFR-mutant lung adenocarcinoma.
Combining EGFR TKIs with an ALPP antibody drug conjugate improves tumor killing, including osimertinib-resistant models.
A rational combination driven by adaptive surfaceome changes.”
Title: Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy.
Authors: Yihui Chen, Rongzhang Dou, Monica J. Hong, Hanwen Xu, Jody Vykoukal, Ricardo A. León-Letelier, Yining Cai, Soyoung Park, Ehsan Irajizad, Fu Chung Hsiao, Jennifer B. Dennison, Edwin J. Ostrin, Johannes F. Fahrmann, Hiroyuki Katayama, Samir M. Hanash
You can read the full article in Cell Reports Medicine.
More posts about Lung Cancer.